Lumos Pharma, Inc.
(NASDAQ : NLNK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.74%306.720.0%$5256.57m
BNTXBioNTech SE 3.17%344.060.0%$1596.83m
NVAXNovavax, Inc. -0.92%160.4878.2%$831.00m
AMGNAmgen, Inc. 0.63%202.441.4%$596.39m
GILDGilead Sciences, Inc. -0.16%69.561.0%$505.86m
REGNRegeneron Pharmaceuticals, Inc. 0.18%635.162.7%$472.48m
VRTXVertex Pharmaceuticals, Inc. -0.31%203.811.9%$464.56m
LGVNLongeveron Inc. 11.78%20.120.0%$429.77m
ILMNIllumina, Inc. -2.85%347.283.3%$324.28m
SNSSSunesis Pharmaceuticals, Inc. -4.21%4.100.7%$286.61m
BIIBBiogen, Inc. -2.01%223.921.8%$276.52m
INCYIncyte Corp. -1.28%65.782.4%$150.25m
SGENSeagen Inc. -5.00%150.745.8%$149.09m
EXASEXACT Sciences Corp. -4.94%76.5918.0%$140.15m
OCGNOcugen, Inc. -8.72%5.760.0%$139.18m

Company Profile

Lumos Pharma, Inc. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Austin, TX.